Estimating the Risk for Secondary Cancer After Targeted α-Therapy with (211)At Intraperitoneal Radioimmunotherapy

Intraperitoneal (211)At-based targeted α-therapy (TAT) may hold great promise as an adjuvant therapy after surgery and chemotherapy in epithelial ovarian cancer to eradicate any remaining undetectable disease. This implies that it will also be delivered to patients possibly already cured by the prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Leidermark, Erik, Hallqvist, Andreas, Jacobsson, Lars, Karlsson, Per, Holmberg, Erik, Bäck, Tom, Johansson, Mia, Lindegren, Sture, Palm, Stig, Albertsson, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841246/
https://www.ncbi.nlm.nih.gov/pubmed/35798559
http://dx.doi.org/10.2967/jnumed.121.263349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841246/
https://www.ncbi.nlm.nih.gov/pubmed/35798559
http://dx.doi.org/10.2967/jnumed.121.263349

Ejemplares similares